{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"72"}],"units":"Participants"}],"description":"Composite time-to-event outcome in which events include moderate or severe chronic GVHD based on National Institute of Health consensus criteria, relapse, or death from any cause.","groups":[{"description":"Patients undergo allogeneic HCT at day 0. Patients with an HLA-matched unrelated donor receive mycophenolate mofetil PO on days 0 to 40, cyclosporine PO every 12 hours BID on days -3 to 96 then tapered to day 150, and sirolimus PO QD on days -3 to day 150 then tapered to day 180. Patients with an HLA-mismatched donor receive mycophenolate mofetil PO on days 0-100 then tapered to day 150, cyclosporine PO BID on days -3 to 150 then tapered to day 180, and sirolimus PO QD on days -3 to 180 then tapered to day 365.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo HCT\n\nCyclosporine: Given PO\n\nMycophenolate Mofetil: Given PO\n\nSirolimus: Given PO","id":"OG000","title":"Arm I (Mycophenolate Mofetil, Cyclosporine, Sirolimus)"},{"description":"Patients undergo HCT at day 0. Patients with an HLA-matched unrelated donor receive cyclosporine PO BID on days 5-96 then tapered to day 150, sirolimus PO QD on days 5-150 then tapered to day 180, and cyclophosphamide IV on days 3 and 4. Patients with an HLA-mismatched donor receive cyclosporine PO BID on days 5-150 then tapered to day 180, sirolimus PO QD on days 5-180 then tapered to day 365, and cyclophosphamide IV on days 3 and 4.\n\nAllogeneic Hematopoietic Stem Cell Transplantation: Undergo HCT\n\nCyclophosphamide: Given IV\n\nCyclosporine: Given PO\n\nSirolimus: Given PO","id":"OG001","title":"Arm II (Cyclosporine, Sirolimus, Cyclophosphamide)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"At 1 year post- hematopoietic cell transplantation (HCT)","title":"Number of Patients With Chronic Graft Versus Host Disease (GVHD)-Free, Relapse-free Survival (CRFS)","type":"PRIMARY","unitOfMeasure":"Participants"}